LT2948559T - Kv1.3 antagonistai ir jų panaudojimo būdai - Google Patents

Kv1.3 antagonistai ir jų panaudojimo būdai

Info

Publication number: LT2948559T
Authority: LT; Lithuania
Prior art keywords: antagonists
Prior art date: 2013-01-25

Application number

LTEP14743871.7T

Other languages

English (en)

Inventor

Ellen Chi

Wilson EDWARDS

Chichi Huang

Wai-Ping Leung

Ronald Swanson

Alan Wickenden

Original Assignee

Janssen Biotech, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-25

Filing date

2014-01-24

Publication date

2018-06-25

2014-01-24 Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.

2018-06-25 Publication of LT2948559T publication Critical patent/LT2948559T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Insects & Arthropods (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)

LTEP14743871.7T 2013-01-25 2014-01-24 Kv1.3 antagonistai ir jų panaudojimo būdai LT2948559T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361756777P	2013-01-25	2013-01-25
US201361757389P	2013-01-28	2013-01-28
PCT/US2014/012932 WO2014116937A1 (en)	2013-01-25	2014-01-24	Kv1.3 antagonists and methods of use

Publications (1)

Publication Number	Publication Date
LT2948559T true LT2948559T (lt)	2018-06-25

Family

ID=51228060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP14743871.7T LT2948559T (lt)	2013-01-25	2014-01-24	Kv1.3 antagonistai ir jų panaudojimo būdai

Country Status (29)

Country	Link
US (2)	US10179808B2 (lt)
EP (1)	EP2948559B1 (lt)
JP (1)	JP6469590B2 (lt)
KR (1)	KR102268830B1 (lt)
CN (1)	CN104937105A (lt)
AU (1)	AU2014209227B2 (lt)
BR (1)	BR112015017795A2 (lt)
CA (1)	CA2898496A1 (lt)
CY (1)	CY1120481T1 (lt)
DK (1)	DK2948559T3 (lt)
EA (1)	EA037308B1 (lt)
ES (1)	ES2671434T3 (lt)
HR (1)	HRP20181055T1 (lt)
HU (1)	HUE039465T2 (lt)
IL (1)	IL239927B (lt)
LT (1)	LT2948559T (lt)
MX (1)	MX365987B (lt)
NZ (1)	NZ709913A (lt)
PH (1)	PH12015501627B1 (lt)
PL (1)	PL2948559T3 (lt)
PT (1)	PT2948559T (lt)
RS (1)	RS57422B1 (lt)
SG (1)	SG11201505508TA (lt)
SI (1)	SI2948559T1 (lt)
SM (1)	SMT201800357T1 (lt)
TR (1)	TR201809377T4 (lt)
UA (1)	UA117824C2 (lt)
WO (1)	WO2014116937A1 (lt)
ZA (1)	ZA201506131B (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6847828B2 (ja) *	2014-08-15	2021-03-24	モナッシュユニバーシティ	新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
CN107530887B (zh)	2015-03-05	2020-11-20	哈佛大学董事会	机器人抓握器、联动装置及用于机器人抓握的方法
WO2017192567A1 (en)	2016-05-02	2017-11-09	Tetragenetics, Inc.	ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF
US10336812B2 (en) *	2016-05-10	2019-07-02	Janssen Biotech, Inc.	GDF15 fusion proteins and uses thereof
TW201808987A (zh) *	2016-06-08	2018-03-16	健生生物科技公司	Ｇｍ－ｃｓｆ變體及使用方法
CN106589092A (zh) *	2016-12-22	2017-04-26	中国科学技术大学先进技术研究院	一种蝎毒素多肽及制备拥有类似天然生理功能的蝎毒素多肽的方法
CN106957357B (zh) *	2017-04-01	2021-02-19	合肥科生景肽生物科技有限公司	一种蝎毒素多肽及其合成方法
JP7539902B2 (ja)	2018-10-22	2024-08-26	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
JP7703520B2 (ja)	2019-09-20	2025-07-07	ジーランド・ファーマ・ア／エス	Ｋｖ１．３遮断剤
AU2022245193A1 (en)	2021-03-23	2023-09-07	Zealand Pharma A/S	Kv1.3 blockers
JP2025534884A (ja)	2022-10-18	2025-10-20	ジーランドファーマエー／エス	阻害剤
WO2026003546A1 (en)	2024-06-27	2026-01-02	Vrg Miniprotein Zrt	Potassium ion kv1.3 channel inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE294860T1 (de)	1997-09-16	2005-05-15	Egea Biosciences Llc	Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6670127B2 (en)	1997-09-16	2003-12-30	Egea Biosciences, Inc.	Method for assembly of a polynucleotide encoding a target polypeptide
GB0414272D0 (en)	2004-06-25	2004-07-28	Cellpep Sa	OsK1 derivatives
MX2007004074A (es)	2004-10-07	2007-08-14	Univ California	Analogos de toxina shk y sus usos en inhibicion selectiva de canales de potasio kv1.3.
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
US7820623B2 (en) *	2006-10-25	2010-10-26	Amgen Inc.	Conjugated toxin peptide therapeutic agents
AU2008262490B2 (en) *	2007-05-22	2011-11-17	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
WO2009075773A2 (en) *	2007-12-07	2009-06-18	Goldstein Steven A	Identification of toxin ligands
WO2010017632A1 (en) *	2008-08-13	2010-02-18	The University Of British Columbia	Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
WO2010108154A2 (en) *	2009-03-20	2010-09-23	Amgen Inc.	Selective and potent peptide inhibitors of kv1.3
US9695228B2 (en) *	2012-11-21	2017-07-04	Janssen Biotech, Inc.	EGFR and c-Met fibronectin type III domain binding molecules

2014
- 2014-01-24 BR BR112015017795A patent/BR112015017795A2/pt not_active IP Right Cessation
- 2014-01-24 RS RS20180808A patent/RS57422B1/sr unknown
- 2014-01-24 EA EA201591380A patent/EA037308B1/ru unknown
- 2014-01-24 KR KR1020157022631A patent/KR102268830B1/ko not_active Expired - Fee Related
- 2014-01-24 SG SG11201505508TA patent/SG11201505508TA/en unknown
- 2014-01-24 DK DK14743871.7T patent/DK2948559T3/en active
- 2014-01-24 WO PCT/US2014/012932 patent/WO2014116937A1/en not_active Ceased
- 2014-01-24 PT PT147438717T patent/PT2948559T/pt unknown
- 2014-01-24 CA CA2898496A patent/CA2898496A1/en not_active Abandoned
- 2014-01-24 HU HUE14743871A patent/HUE039465T2/hu unknown
- 2014-01-24 LT LTEP14743871.7T patent/LT2948559T/lt unknown
- 2014-01-24 SI SI201430719T patent/SI2948559T1/en unknown
- 2014-01-24 JP JP2015555340A patent/JP6469590B2/ja not_active Expired - Fee Related
- 2014-01-24 AU AU2014209227A patent/AU2014209227B2/en not_active Ceased
- 2014-01-24 PL PL14743871T patent/PL2948559T3/pl unknown
- 2014-01-24 CN CN201480006077.8A patent/CN104937105A/zh active Pending
- 2014-01-24 ES ES14743871T patent/ES2671434T3/es active Active
- 2014-01-24 UA UAA201508231A patent/UA117824C2/uk unknown
- 2014-01-24 EP EP14743871.7A patent/EP2948559B1/en active Active
- 2014-01-24 US US14/163,158 patent/US10179808B2/en not_active Expired - Fee Related
- 2014-01-24 TR TR2018/09377T patent/TR201809377T4/tr unknown
- 2014-01-24 NZ NZ709913A patent/NZ709913A/en not_active IP Right Cessation
- 2014-01-24 SM SM20180357T patent/SMT201800357T1/it unknown
- 2014-01-24 MX MX2015009632A patent/MX365987B/es active IP Right Grant
- 2014-01-24 HR HRP20181055TT patent/HRP20181055T1/hr unknown
2015
- 2015-07-14 IL IL239927A patent/IL239927B/en active IP Right Grant
- 2015-07-23 PH PH12015501627A patent/PH12015501627B1/en unknown
- 2015-08-24 ZA ZA2015/06131A patent/ZA201506131B/en unknown
2018
- 2018-07-31 CY CY20181100787T patent/CY1120481T1/el unknown
- 2018-09-07 US US16/124,295 patent/US20190062383A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN104937105A (zh)	2015-09-23
US10179808B2 (en)	2019-01-15
PH12015501627A1 (en)	2015-09-21
EA037308B1 (ru)	2021-03-10
EP2948559B1 (en)	2018-05-02
ES2671434T3 (es)	2018-06-06
KR20150108912A (ko)	2015-09-30
UA117824C2 (uk)	2018-10-10
KR102268830B1 (ko)	2021-06-24
CA2898496A1 (en)	2014-07-31
CY1120481T1 (el)	2019-07-10
AU2014209227B2 (en)	2017-11-23
PT2948559T (pt)	2018-07-24
EP2948559A1 (en)	2015-12-02
SI2948559T1 (en)	2018-08-31
AU2014209227A1 (en)	2015-07-30
US20190062383A1 (en)	2019-02-28
DK2948559T3 (en)	2018-05-28
PH12015501627B1 (en)	2020-12-11
HUE039465T2 (hu)	2019-01-28
HRP20181055T1 (hr)	2018-09-07
ZA201506131B (en)	2017-06-28
MX365987B (es)	2019-06-20
US20140255401A1 (en)	2014-09-11
SMT201800357T1 (it)	2018-09-13
RS57422B1 (sr)	2018-09-28
IL239927B (en)	2020-10-29
JP2016505639A (ja)	2016-02-25
WO2014116937A1 (en)	2014-07-31
IL239927A0 (en)	2015-08-31
JP6469590B2 (ja)	2019-02-13
MX2015009632A (es)	2015-11-30
BR112015017795A2 (pt)	2017-11-21
EP2948559A4 (en)	2016-10-19
NZ709913A (en)	2019-05-31
TR201809377T4 (tr)	2018-07-23
SG11201505508TA (en)	2015-08-28
PL2948559T3 (pl)	2018-09-28
EA201591380A1 (ru)	2015-12-30

Publication	Publication Date	Title
NO2023013I1 (no)	2023-03-20	Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
LT2948559T (lt)	2018-06-25	Kv1.3 antagonistai ir jų panaudojimo būdai
LT2970303T (lt)	2017-07-25	Pakeistieji ksantinai ir jų panaudojimo metodai
LT3116909T (lt)	2020-02-10	Antikūno molekulės prieš lag-3 ir jų panaudojimas
LT3317284T (lt)	2020-01-27	Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT2968443T (lt)	2021-12-10	Hepcidino analogai ir jų naudojimas
IL245036B (en)	2020-10-29	Pesticidal compositions and related methods
LT3003039T (lt)	2021-05-10	Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
LT2989088T (lt)	2018-01-10	Dolastatino 10 ir auristatinų dariniai
LT3319612T (lt)	2021-08-25	Oksisteroliai ir jų naudojimo būdai
DK3143037T3 (da)	2021-09-20	Alpha4beta7-integrin-thioether-peptidantagonister
DK2961835T3 (da)	2019-07-22	Ny bakteriophag og antibakteriel sammensætning omfattende samme
LT3030519T (lt)	2022-04-11	Tricikliniai benzoksaborolo junginiai ir jų naudojimas
PL3331063T3 (pl)	2021-11-02	Akumulator i zespół akumulatorowy
LT3337506T (lt)	2021-10-11	Deriniai ir jų panaudojimas
LT3247711T (lt)	2022-05-25	Naujos scy-078 druskos ir polimorfai
FR3004424B1 (fr)	2015-05-29	Marchepied amovible d'aeronef, et aeronef
LT3060660T (lt)	2021-07-26	Rekombinantiniai glikoproteinai ir jų naudojimas
LT3066091T (lt)	2019-07-10	Nmda antagonistų pirmtakai
EP3298014A4 (en)	2019-05-15	S1pr2 antagonists and uses therefor
LT3140318T (lt)	2020-01-10	Kv1.3 kalio kanalų antagonistai
DK3658413T3 (da)	2021-11-08	Godssikringsenhed
FI20145740A7 (fi)	2016-02-27	Sovitelma puomistossa
ME03086B (me)	2019-01-20	Antagonisтi kv1.3 i postupci za upotrebu
LT3518927T (lt)	2021-01-25	1-fenilpropanono junginiai ir jų panaudojimas